Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Agennix logo — Crafting novel therapies to enhance the length and quality o...

Agennix

Crafting novel therapies to enhance the length and quality of life for seriously ill patients worldwide.

Founded 1993 Venture round Total: $111.00M Biopharma, Biotechnology +2

General Information

Company Name Agennix
Founded Year 1993
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Agennix. To contact Agennix, visit agennix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Agennix compare?

A PDF of Agennix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Agennix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Agennix

Agennix is a publicly traded biopharmaceutical company that was founded in 1993. The company's primary focus is on developing innovative therapies for significant unmet medical needs, with the aim of enhancing both the duration and quality of life for seriously ill patients. Its leading program, talactoferrin, has shown efficacy in randomized, double-blind, placebo-controlled Phase 2 studies for non-small cell lung cancer and severe sepsis, and is currently undergoing Phase 3 clinical trials for non-small cell lung cancer. In addition to talactoferrin, Agennix is also involved in the clinical development of RGB-286638, a multi-targeted kinase inhibitor; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. The company operates from its headquarters in Heidelberg, Germany, with additional operational sites in Martinsried/Munich, Germany; Princeton, New Jersey; and Houston, Texas. Agennix received a €76.00M Venture Round investment on 01 October 2010. With its focus on addressing unmet medical needs and promising pipeline of therapies, Agennix holds potential for growth and impact in the biopharma, biotechnology, healthcare, and pharmaceutical industries.

Taxonomy: Biopharmaceutical, Therapies, Clinical trials, Phase 3, Cancer treatment, Drug development, Innovative therapies, Medicine, Life quality, Patient care, Publicly traded company, Medical research, Germany, United States

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round €76.00M -
01 Oct 2010
Venture Round $13.00M -
22 Mar 2010
Venture Round $22.00M -
31 Mar 2005

Agennix Alternatives & Competitors

View All Alternatives
Agennix vs
Curis
Curis United States

Working relentlessly to develop innovative and differentiated therapeutics that improve the lives of...

Post-IPO Equity
133 employees
Biotechnology, Health Care
Agennix vs
Day One Biopharmaceuticals
Day One Biopharmaceuticals United States

Cancer drug development comes of age.

Post-IPO Equity
190 employees
Biopharma, Biotechnology
Agennix vs
Anchiano Therapeutics
Anchiano Therapeutics United States

Dedicated to the discovery, development, and commercialization of novel targeted therapies to treat...

Post-IPO Equity
1 employees
Biotechnology, Health Care
View all alternatives

FAQ About Agennix

Crafting novel therapies to enhance the length and quality of life for seriously ill patients worldwide.
Agennix was founded in 1993.
Agennix operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on Biopharmaceutical, Therapies, Clinical trials and Phase 3.
Agennix has completed 3 funding rounds, raising a total of $111.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Agennix include Curis, Day One Biopharmaceuticals, Anchiano Therapeutics, Developing New Drugs for AML and PDAC, Apollomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Agennix and Curis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Agennix, https://bouncewatch.com/company/agennix, updated 11 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes